Appl. No. Filed

09/665,728

September 20, 2000

polynucleotide detects, by microarray analysis, a polynucleotide that is differentially expressed by at least about 1.8-fold in an in vivo or in vitro myocardial infarction disease model;

- (c) a polynucleotide encoding a polypeptide having at least 90% sequence identity with amino acids 56 to 122 of SEQ ID NO:1, wherein the complement of said polynucleotide detects, by microarray analysis, a polynucleotide that is differentially expressed by at least about 1.8-fold in an in vivo or in vitro myocardial infarction disease model;
- (d) a polynucleotide encoding amino acids 22 to 275 of SEQ ID NO:1, or a transmembrane domain deleted or inactivated variant thereof, wherein the complement of said polynucleotide detects, by microarray analysis, a polynucleotide that is differentially expressed by at least about 1.8-fold in an in vivo or in vitro myocardial infarction disease model;
- (e) a polynucleotide encoding at least about 50 contiguous amino acids from amino acids 22 to 122 of SEQ ID NO:1, wherein the complement of said polynucleotide detects, by microarray analysis, a polynucleotide that is differentially expressed by at least about 1.8-fold in an in vivo or in vitro myocardial infarction disease model;
- (f) a polynucleotide encoding at least about 50 contiguous amino acids from amino acids 56 to 122 of SEQ ID NO:1, wherein the complement of said polynucleotide detects, by microarray analysis, a polynucleotide that is differentially expressed by at least about 1.8-fold in an in vivo or in vitro myocardial infarction disease model; and
 - (g) the complement of a polynucleotide of (a) (f).
- 2. (Twice amended) The polynucleotide of claim 1 encoding a polypeptide comprising amino acids 22 to 122 of SEQ ID NO:1, wherein the complement of said polynucleotide detects, by microarray analysis, a polynucleotide that is differentially expressed by at least about 1.8-fold in an in vivo or in vitro myocardial infarction disease model.
- 3. (Twice amended) The polynucleotide of claim 1 encoding a polypeptide comprising amino acids 56 to 122 of SEQ ID NO:1, wherein the complement of said polynucleotide detects, by microarray analysis, a polynucleotide that is differentially expressed by at least about 1.8-fold in an in vivo or in vitro myocardial infarction disease model.

Appl. No.

09/665,728

Filed

September 20, 2000

4. (Twice amended) The polynucleotide of claim 1 encoding a polypeptide comprising the sequence of SEQ ID NO:1, wherein the complement of said polynucleotide detects, by microarray analysis, a polynucleotide that is differentially expressed by at least about 1.8-fold in an in vivo or in vitro myocardial infarction disease model.

- 30. (Amended) An isolated polynucleotide encoding a polypeptide comprising a native mammalian homologue having at least 90% amino acid sequence identity to SEQ ID NO:1, wherein the complement of said polynucleotide detects, by microarray analysis, a polynucleotide that is differentially expressed by at least about 1.8-fold in an in vivo or in vitro myocardial infarction disease model.
- 32. (Amended) An isolated polynucleotide that hybridizes to the coding region of SEQ ID NO:2 under stringent hybridization conditions of 50% formamide, 5x SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, 50 μg/ml salmon sperm DNA, 0.1% SDS, and 10% dextran sulfate at 42°C, and wash conditions of 0.2x SSC and 50% formamide at 55°C, followed by 0.1x SSC with EDTA at 55°C, wherein the complement of said polynucleotide detects, by microarray analysis, a polynucleotide that is differentially expressed by at least about 1.8-fold in an in vivo or in vitro myocardial infarction disease model.

REMARKS

Claims 1-8 and 30-33 are pending. Claims 1-4, 30, and 32 have been amended. No new matter was introduced by way of these amendments and the amended claims are supported by the specification, especially Example 1, and the claims as originally filed. Reconsideration of the present application is requested.

<u>Telephonic Interview</u>

Applicants thank the Examiner for the courtesy shown during the telephonic interview conducted on December 23, 2002. No agreement was reached regarding the subject matter of the pending claims. Nevertheless, the general subject matter of the telephonic interview has been incorporated into the body of the present Amendment and Response.